about
Use-dependent inhibition of the skeletal muscle ryanodine receptor by the suramin analogue NF676Phosphorylation of serine 2843 in ryanodine receptor-calcium release channel of skeletal muscle by cAMP-, cGMP- and CaM-dependent protein kinase.Inhibition of receptor/G protein coupling by suramin analogues.Pharmacological activation of the ryanodine receptor in Jurkat T-lymphocytesGsalpha-selective G protein antagonists.In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatinNicotinic acid adenine dinucleotide phosphate (NAADP)-mediated calcium signaling and arrhythmias in the heart evoked by β-adrenergic stimulation.Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells.Novel and current treatment concepts using pulmonary drug delivery.Drug induced rhabdomyolysis.Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor.Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cellsAutocrine secretion of 15d-PGJ2 mediates simvastatin-induced apoptotic burst in human metastatic melanoma cells.Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells.Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.Channelling of substrate promiscuity of the skeletal-muscle ADP-ribosyl cyclase isoform.Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells.Metal-dependent nucleotide binding to the Escherichia coli rotamase SlyD.Activation and labelling of the purified skeletal muscle ryanodine receptor by an oxidized ATP analogue.2',3'-Dialdehyde GTP as an irreversible G protein antagonist. Disruption and reconstitution of G protein-mediated signal transduction in cells and cell membranes.Nicotinic acid-adenine dinucleotide phosphate activates the skeletal muscle ryanodine receptor.Store operated Ca2+ influx by selective depletion of ryanodine sensitive Ca2+ pools in primary human skeletal muscle cells.No evidence for direct modulatory effects of delta 9-tetrahydrocannabinol on human polymorphonuclear leukocytes.Covalent modification of G-proteins by affinity labeling.Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells.I like to move it, move it.Extracellular ATP activates ERK1/ERK2 via a metabotropic P2Y1 receptor in a Ca2+ independent manner in differentiated human skeletal muscle cells.Dihydropyridine-induced Ca2+ release from ryanodine-sensitive Ca2+ pools in human skeletal muscle cells.Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose.Structural and functional characterization of the interaction between 2',3'-dialdehyde guanine nucleotide analogues and the stimulatory G protein alpha-subunit.Amino Acid Signature in Human Melanoma Cell Lines from Different Disease Stages.Statins reduce endogenous dolichol levels in the neuroblastoma cell line SH-SY5YSuramin analogues as subtype-selective G protein inhibitors[Calcium channel mediated calcium release from the rabbit skeletal muscle sarcoplasmic reticulum vesicle]2',3'-Dialdehyde ATP analog labels the Ca(2+)-ATPase of sarcoplasmic reticulum via the catalytic adenosine-nucleotide-binding siteThiophosphorylation of the G protein beta subunit in human platelet membranes: evidence against a direct phosphate transfer reaction to G alpha subunitsSpecies differences in A1 adenosine receptor/G protein coupling: identification of a membrane protein that stabilizes the association of the receptor/G protein complexActivation of the skeletal muscle ryanodine receptor by suramin and suramin analogsSuramin and suramin analogs activate skeletal muscle ryanodine receptor via a calmodulin binding siteThe C2 catalytic domain of adenylyl cyclase contains the second metal ion (Mn2+) binding site
P50
Q24676296-B607380D-478F-442E-A640-591014D30F05Q34355057-60D83177-01F2-4721-8448-63F60E1BE422Q34388145-8B6B17FD-AD87-415A-BA72-54BDDC92DE6DQ35041711-D837D672-3D8D-4877-A69A-E01A9F9E62A2Q35679024-35777482-90FC-43E6-BDA1-AD230EE430C2Q36427010-06FAFE18-178F-4839-B81D-452B8E94E060Q36890713-953B2499-898F-470D-A904-E8C3E5534052Q36913097-0D29386E-D78C-4083-9F79-F252C9436EDDQ37761394-DC6636CD-AE87-44BB-B903-0BF21A86AE84Q38007737-C26DC31E-DA4F-4A17-855F-67E508B7CE63Q38301070-8ACCB1AE-A1F6-400C-995F-BF9B02C10197Q38870044-44FAE99E-B5F1-426E-97A3-9E8F171D222FQ38968834-01C81B02-3887-45AB-9464-F446AA40D831Q39801830-6F29F379-02BE-4EE5-A6E8-2A4585D52195Q39831618-57C6E756-F1A6-4A77-A980-07FD27A14AD4Q40567022-B0E6D6CB-A0FC-4CA7-8056-C1A7A415BD2BQ41844170-B5B242F7-BBFC-4367-9003-D2322DA18847Q41875702-C290BEFC-B8C2-4DDB-874C-B7C223EBC346Q41985303-6410C810-0EEB-4211-A854-244F1DA81A29Q42494050-ABB0E07E-048D-48B8-BAE4-29F420B063DFQ43002260-7185224B-E293-4D68-A1CF-D4937CE61FAAQ44400229-03DA116D-8C8D-4D75-BED8-59B4D70782CBQ44579217-A163B903-D290-483E-B830-8FE8C2BB4DB7Q44975800-600806DD-C85C-4D05-A083-D80C96E50B76Q46508413-B8A8DCBA-FF81-46BB-A1CC-0B9845880619Q46590001-8E3CCF64-223E-4A2C-80FA-F27568C89A3FQ46988133-86F0E5D8-6AFF-45AB-8B6C-5CE697C59E8CQ51398691-8A59DC07-7911-4A98-B723-265926B8C113Q53935821-FCBC0201-A597-4476-95B8-02049FC5ED71Q54412498-B0CE6A68-B1EB-43C8-8A76-443DCA2C3697Q55091781-60B36047-38C9-46EB-8145-7DB52E09D273Q59826249-B802D74C-F06F-47AD-BF89-E828B0C90C88Q63916791-A5199206-A1A5-42BC-A20B-AF73061EA41CQ67676901-A53E8530-A5FE-4751-95C8-6CC7662C195BQ68054259-678761AC-D468-4D76-88FB-3793F618027FQ70920215-F1BA52D5-7878-4D3C-B916-FE56F1C0E51CQ71522816-FA7F9876-05F6-4284-8A5E-D006989A268AQ71899647-FA326C83-8A1F-4E8A-B5D6-61C0B76F3EA8Q74530107-7BAC15C0-41D7-48E1-8180-D56129D57CA6Q77569569-35431FE2-4FD0-4201-BA0D-F22842B7FA5D
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Martin Hohenegger
@ast
Martin Hohenegger
@en
Martin Hohenegger
@es
Martin Hohenegger
@nl
Martin Hohenegger
@sl
type
label
Martin Hohenegger
@ast
Martin Hohenegger
@en
Martin Hohenegger
@es
Martin Hohenegger
@nl
Martin Hohenegger
@sl
prefLabel
Martin Hohenegger
@ast
Martin Hohenegger
@en
Martin Hohenegger
@es
Martin Hohenegger
@nl
Martin Hohenegger
@sl
P106
P21
P31
P496
0000-0001-6537-9574